摘要
目的:探讨细胞色素P450(CYP)2D6 C188T基因多态性与难治性抑郁症及氟西汀合并小剂量利培酮治疗的疗效、不良反应的关联。方法:应用聚合酶链反应(PCR)扩增技术及限制性片段长度多态性(RFLP)测定92例难治性抑郁症患者及107名正常对照的CYP2D6 C188T基因多态性。其中59例患者接受氟西汀合并小剂量利培酮治疗6周,进一步分析不同疗效或不良反应患者的CYP2D6 C188T基因多态性。结果:难治性抑郁症患者与健康对照组CYP2D6C188T基因型及等位基因分布差异无统计学意义。36例有效患者的T等位基因频率(n=40,55.6%)高于23例无效患者的(n=14,30.4%),(χ2=7.14,P=0.01);33例有不良反应患者的T等位基因频率(n=46,69.7%)高于26例无不良反应患者的(n=26,50.0%),(χ2=4.74,P=0.03)。结论:CYP2D6 C188T基因多态性与难治性抑郁症无显著关联,但可能是影响利培酮对氟西汀增效作用以及两药联用的不良反应。
Objective：To investigate the association between cytochrome p450（CYP）2D6 C188T gene polymorphism and treatment-resistant depression and it＇s therapeutic response.Method：Polymerase chain reaction and restriction fragment length polymorphism techniques were used to examine the CYP2D6 C188T gene polymorphism of 92 treatment-resistant depression patients and 107 healthy controls.Within the patients,there were 59 accepted the risperidone augmentation of fluoxetine.Results：There was no significant difference between the treatment-resistant depression patients and the healthy controls in CYP2D6 C188T genotypes and alleles.According there response to the therapy,59 patients were divided into response and non-response groups.The frequency of T allele in treatment response group（n=40,55.6%） was significantly higher than the group of non-response（n=14,30.4%）（χ2=7.14,P=0.01）.The T allele of CYP2D6 C188T of the patients who had side-effect（n=46,69.7%） was significantly higher than those who hadn＇t side-effect（n=26,50.0%）（χ2=4.74,P=0.03）.Conclusion：The results suggested that there was no association with treatment-resistant depression and CYP2D6 C188T gene polymorphism.The T allele of CYP2D6 C188T may affect the augmentative effect and side effect of the risperidone to fluoxetine.
出处
《临床精神医学杂志》
2011年第4期226-229,共4页
Journal of Clinical Psychiatry
